Goldman Sachs
TBPH icon

Goldman Sachs’s Theravance Biopharma TBPH Stock Holding History

Goldman Sachs’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$561K – 6222
2022
Q4 		$561K Hold
50,000
– – ﹤0.01% 4809
2022
Q3 		$507K Buy
+50,000
New +$469K ﹤0.01% 4961

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's TBPH Position: Q1 2026 in Review

Goldman Sachs increased its Theravance Biopharma (TBPH) stake by 43% in Q1 2026, buying an estimated $2.22M and bringing the position to 416,143 shares worth $6.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3408.

Goldman Sachs first reported a position in TBPH in Q2 2014 and has held it in 44 quarters since. The position peaked at $11.4M in Q1 2018. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Goldman Sachs held 416,143 shares of Theravance Biopharma worth $6.75M as of Q1 2026.
  • Goldman Sachs bought 125,279 Theravance Biopharma shares in Q1 2026, an estimated $2.22M.
  • Theravance Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3408 holding.
  • Goldman Sachs first reported a position in Theravance Biopharma in Q2 2014 and has held it in 44 quarters since.
  • Goldman Sachs's Theravance Biopharma position peaked at $11.4M in Q1 2018.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.